Inhibition of Polo-like Kinase 1 by Blocking Polo-Box Domain-Dependent Protein-Protein Interactions

Chemistry and Biology

Volumn 15, Issue 5, 2008, Pages 459-466

  Reindl, Wolfgang ^a   Yuan, Juping ^b   Krämer, Andrea ^b   Strebhardt, Klaus ^b   Berg, Thorsten ^a  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

CHEMBIO; SIGNALING

Indexed keywords

EID: 43149093993     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2008.03.013     Document Type: Article

References (36)

1. F.A. Barr H.H. Sillje E.A. Nigg Polo-like kinases and the orchestration of cell division Nat. Rev. Mol. Cell Biol. 5 2004 429 440
2. K.Y. Cheng E.D. Lowe J. Sinclair E.A. Nigg L.N. Johnson The crystal structure of the human polo-like kinase-1 polo box domain and its phospho-peptide complex EMBO J. 22 2003 5757 5768
3. D.R. Coleman Z. Ren P.K. Mandal A.G. Cameron G.A. Dyer S. Muranjan M. Campbell X. Chen J.S. McMurray Investigation of the binding determinants of phosphopeptides targeted to the Src homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor J. Med. Chem. 48 2005 6661 6670
4. T.W. Corson C.M. Crews Molecular understanding and modern application of traditional medicines: triumphs and trials Cell 130 2007 769 774
5. H. Daub K. Specht A. Ullrich Strategies to overcome resistance to targeted protein kinase inhibitors Nat. Rev. Drug Discov. 3 2004 1001 1010
6. D. Durocher I.A. Taylor D. Sarbassova L.F. Haire S.L. Westcott S.P. Jackson S.J. Smerdon M.B. Yaffe The molecular basis of FHA domain:phosphopeptide binding specificity and implications for phospho-dependent signaling mechanisms Mol. Cell 6 2000 1169 1182
7. A.E. Elia L.C. Cantley M.B. Yaffe Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates Science 299 2003 1228 1231
8. A.E. Elia P. Rellos L.F. Haire J.W. Chao F.J. Ivins K. Hoepker D. Mohammad L.C. Cantley S.J. Smerdon M.B. Yaffe The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain Cell 115 2003 83 95
9. J. Fink K. Sanders A. Rippl S. Finkernagel T.L. Beckers M. Schmidt Cell type-dependent effects of Polo-like kinase 1 inhibition compared with targeted polo box interference in cancer cell lines Mol. Cancer Ther. 6 2007 3189 3197
10. H. Gali-Muhtasib A. Roessner R. Schneider-Stock Thymoquinone: a promising anti-cancer drug from natural sources Int. J. Biochem. Cell Biol. 38 2006 1249 1253
11. K. Gumireddy M.V. Reddy S.C. Cosenza R. Boominathan S.J. Baker N. Papathi J. Jiang J. Holland E.P. Reddy ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent Cancer Cell 7 2005 275 286
12. M. Hafner A. Schmitz I. Grune S.G. Srivatsan B. Paul W. Kolanus T. Quast E. Kremmer I. Bauer M. Famulok Inhibition of cytohesins by SecinH3 leads to hepatic insulin resistance Nature 444 2006 941 944
13. A. Hanisch A. Wehner E.A. Nigg H.H. Sillje Different Plk1 functions show distinct dependencies on Polo-Box domain-mediated targeting Mol. Biol. Cell 17 2006 448 459
14. N. Jiang X. Wang M. Jhanwar-Uniyal Z. Darzynkiewicz W. Dai Polo box domain of Plk3 functions as a centrosome localization signal, overexpression of which causes mitotic arrest, cytokinesis defects, and apoptosis J. Biol. Chem. 281 2006 10577 10582
15. A.O. Kaseb K. Chinnakannu D. Chen A. Sivanandam S. Tejwani M. Menon Q.P. Dou G.P. Reddy Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer Cancer Res. 67 2007 7782 7788
16. A. Kiessling B. Sperl A. Hollis D. Eick T. Berg Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules Chem. Biol. 13 2006 745 751
17. T.J. Lansing R.T. McConnell D.R. Duckett G.M. Spehar V.B. Knick D.F. Hassler N. Noro M. Furuta K.A. Emmitte T.M. Gilmer In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1 Mol. Cancer Ther. 6 2007 450 459
18. P. Lenart M. Petronczki M. Steegmaier B. Di Fiore J.J. Lipp M. Hoffmann W.J. Rettig N. Kraut J.M. Peters The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1 Curr. Biol. 17 2007 304 315
19. X. Liu R.L. Erikson Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells Proc. Natl. Acad. Sci. USA 100 2003 5789 5794
20. Y. Liu K.R. Shreder W. Gai S. Corral D.K. Ferris J.S. Rosenblum Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase Chem. Biol. 12 2005 99 107
21. C. McInnes M. Mezna P.M. Fischer Progress in the discovery of polo-like kinase inhibitors Curr. Top. Med. Chem. 5 2005 181 197
22. C. McInnes A. Mazumdar M. Mezna C. Meades C. Midgley F. Scaerou L. Carpenter M. Mackenzie P. Taylor M. Walkinshaw Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance Nat. Chem. Biol. 2 2006 608 617
23. J.C. Owicki Fluorescence polarization and anisotropy in high throughput screening: perspectives and primer J. Biomol. Screen. 5 2000 297 306
24. U. Peters J. Cherian J.H. Kim B.H. Kwok T.M. Kapoor Probing cell-division phenotype space and Polo-like kinase function using small molecules Nat. Chem. Biol. 2 2006 618 626
25. V. Rishi T. Potter J. Laudeman R. Reinhart T. Silvers M. Selby T. Stevenson P. Krosky A.G. Stephen A. Acharya A high-throughput fluorescence-anisotropy screen that identifies small molecule inhibitors of the DNA binding of B-ZIP transcription factors Anal. Biochem. 340 2005 259 271
26. A. Santamaria R. Neef U. Eberspacher K. Eis M. Husemann D. Mumberg S. Prechtl V. Schulze G. Siemeister L. Wortmann Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis Mol. Biol. Cell 18 2007 4024 4036
27. A. Schmidt N.R. Rauh E.A. Nigg T.U. Mayer Cytostatic factor: an activity that puts the cell cycle on hold J. Cell Sci. 119 2006 1213 1218
28. J. Schust T. Berg A high-throughput fluorescence polarization assay for signal transducer and activator of transcription 3 Anal. Biochem. 330 2004 114 118
29. J. Schust B. Sperl A. Hollis T.U. Mayer T. Berg Stattic: a small-molecule inhibitor of STAT3 activation and dimerization Chem. Biol. 13 2006 1235 1242
30. B. Spankuch-Schmitt J. Bereiter-Hahn M. Kaufmann K. Strebhardt Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells J. Natl. Cancer Inst. 94 2002 1863 1877
31. B. Spankuch-Schmitt G. Wolf C. Solbach S. Loibl R. Knecht M. Stegmuller G. von Minckwitz M. Kaufmann K. Strebhardt Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells Oncogene 21 2002 3162 3171
32. M. Steegmaier M. Hoffmann A. Baum P. Lenart M. Petronczki M. Krssak U. Gurtler P. Garin-Chesa S. Lieb J. Quant BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo Curr. Biol. 17 2007 316 322
33. C.S. Stevenson E.A. Capper A.K. Roshak B. Marquez C. Eichman J.R. Jackson M. Mattern W.H. Gerwick R.S. Jacobs L.A. Marshall The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore J. Pharmacol. Exp. Ther. 303 2002 858 866
34. K. Strebhardt A. Ullrich Targeting polo-like kinase 1 for cancer therapy Nat. Rev. Cancer 6 2006 321 330
35. M.B. Yaffe M. Schutkowski M. Shen X.Z. Zhou P.T. Stukenberg J.U. Rahfeld J. Xu J. Kuang M.W. Kirschner G. Fischer Sequence-specific and phosphorylation-dependent proline isomerization: a potential mitotic regulatory mechanism Science 278 1997 1957 1960
36. J. Yuan A. Kramer F. Eckerdt M. Kaufmann K. Strebhardt Efficient internalization of the polo-box of polo-like kinase 1 fused to an Antennapedia peptide results in inhibition of cancer cell proliferation Cancer Res. 62 2002 4186 4190